Difference between revisions of "Mianserine-duloxetine"
From Psychiatrienet
| Line 3: | Line 3: | ||
| to = duloxetine | | to = duloxetine | ||
| stop = | | stop = | ||
| − | * ''' | + | * '''Before day 1:''' gradually reduce dosage of mianserine to a maximum of 60 mg/ day. |
* '''Day 1:''' reduce a dosage of 60 mg/day to 30 mg/day. | * '''Day 1:''' reduce a dosage of 60 mg/day to 30 mg/day. | ||
| start = | | start = | ||
Latest revision as of 15:09, 17 November 2009
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from mianserine to duloxetine.[1] [2]
Stop mianserine - Before day 1: gradually reduce dosage of mianserine to a maximum of 60 mg/ day.
- Day 1: reduce a dosage of 60 mg/day to 30 mg/day.
Start duloxetine- Day 1: simultaneously start duloxetine in a low dosage of 30 mg/day.
- Day 8: stop administration of mianserine and only continue administration of duloxetine in a dosage of 60 mg/day.
- If necessary, increase the dosage of duloxetine.
More information- Caution with this switch is necessary, because duloxetine slows the metabolism of mianserine via CYP2D6.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
